Table 5 Vitamin K prophylaxis regimens and associated incidence of HDN from surveillance data in Europe

 1994 to June 2000

2 mg po at birth, 1 mg po weekly for 3 months

0.0 (0 to 0.9)

 After June 2000

2 mg IM at birth

Not available

France

2 mg po weekly for 6 weeks

Not available

Germany

2 mg po for 3 doses: days 1, 4–10 and 28–42

0.44 (0.2 to 0.9)

Netherlands

(A) 1 mg po at birth, 25 μg po daily from week 2 to 13

(B) 1 mg po at birth, 150 μg po daily from week 2 to 13

(A) 3.2 (1.2 to 6.9)

Intracranial HDN, general and targeted surveillance

(A) 1.6 (0.4 to 5.1) and 3.1 (1.9 to 5.0)

(B) 1.3 (0.5 to 3.2) and 1.2 (0.6 to 2.3)

United Kingdom

1 mg IM at birth

0.1

2 mg po for 3 doses: day 1, weeks 1 and 4

0.43

Spain

1 mg IM at birth

‘Almost inexistent’^a

Switzerland

2 mg po for 3 doses: day 1, day 4, week 4

0.0 (0.0 to 0.81)^b [16]

1.09 (0.4 to 2.6) [17]